Sam-4-Bio Samarium Diiodide Catalysis for Novel Bioiosteres
- Coordinator
- The University of Manchester, United Kingdom
- Runs
- 1 June 2025 to 31 May 2027
- Status
- Running
- EU funding
- €276k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101210543
What the project is doing
In the project's own words, from its summary on CORDIS.
The concept of bioisosteric replacement of arene pharmacophores in drug candidates has garnered increasing attention as a powerful tool to circumvent the production of toxic metabolites through detrimental metabolic modifications of the arene backbone. Replacement of the arene core in drug candidates with rigid, C(sp3)-rich bioisosteric scaffold improves their metabolic stability, potency, lipophilicity, and solubility.
Crucially, cage-like structures with defined exit vectors renders them bioisosteres with superior ability to dock in the chiral binding pocket of the target receptor. Therefore, the demand for C(sp3)-rich bioisosteric replacements is skyrocketing and recent endeavors have provided a variety of decorated saturated systems mimicking substituted arenes. While initial studies were mostly directed towards bioisosteres of mono- and para-substituted arenes, recent efforts have focussed more on bioisosteres for ortho- and meta-substituted aromatic rings.
Despite the significant development of synthetic strategies for preparing already proven bioisosteres, the lack of synthetic methods to access many unexplored analogues, such as bicyclo[2.2.1]heptanes (BCHeps), renders their potential undetermined to date. Consequently, developing general, catalytic, sustainable methods for rapidly accessing 1,2-BCHeps is an urgent necessity. Recent breakthroughs from the Procter group have set a new benchmark by applying radical relay catalysis using SmI2 for accessing bioisosteric scaffolds.
Sam-4-Bio will integrate this novel concept with the group’s recent finding of enhancing catalytic efficiency of SmI2 by photoactivation, to develop a catalytic platform for accessing unexplored bioisosteres of ortho-arenes like 1,2-BCHeps. Challenging insertion of alkene into the bridgehead bond of strained housane ketones under SmI2-catalysis will deliver key intermediates for downstream manipulation en route to new saturated analogues of validated drugs with superior bioactivity.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| The University of Manchester | Manchester | United Kingdom | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI